Drawing for MIRACLE BIOTICS

USPTO serial 87700040

MIRACLE BIOTICS

Reviewed by CopyMark Law Group

Status 601
Filing date
Status date
Registration date
—
Examiner
QUEEN, ESTHER FELICIA
Law office
TMO LAW OFFICE 111 - EXAMINING ATTORNEY ASSIGNED

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with MIRACLE BIOTICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Sirina Tsai

SIRINA TSAI NEWMAN DU WORS2101 FOURTH AVENUE, SUITE 1500SEATTLE, WA 98121UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Dietary and nutritional supplements; Herbal male enhancement supplements; Dietary and nutritional supplements, namely, male enhancement supplements; Dietary supplements for urinary healthACTIVEJan 31, 2017

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 11, 2018MAB1ABANDONMENT NOTICE MAILED - EXPRESS ABANDONMENT—
Apr 11, 2018ABN1ABANDONMENT - EXPRESS MAILED—
Apr 10, 2018EXARTEAS EXPRESS ABANDONMENT RECEIVED—
Mar 13, 2018GEANNOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED—
Mar 13, 2018GEAPEXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED—
Mar 13, 2018EPENCOMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY—
Mar 13, 2018CPEAEXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED—
Mar 12, 2018DOCKASSIGNED TO EXAMINER—
Dec 8, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 1, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance